论文部分内容阅读
目的探讨对乙型肝炎e抗原(HBe Ag)低效价慢性乙型肝炎患者行阿德福韦酯联合聚乙二醇干扰素α-2a治疗的具体功效。方法 50例HBe Ag低效价慢性乙型肝炎患者,随机分为对照组与试验组,每组25例。对照组患者单纯采用阿德福韦酯治疗,试验组患者在阿德福韦酯治疗基础上辅以聚乙二醇干扰素α-2a治疗。治疗后的24周和48周对患者疗效进行评估,对比两种方案的具体治疗功效。结果对照组和试验组患者接受不同的治疗后,病情均得到了不同程度的缓解。治疗48周后,病毒学应答HBV-DNA转换对照组有15例,试验组有23例,组间比较差异有统计学意义(P<0.05)。HBs Ag血清学转换对照组6例,试验组13例,组间差异有统计学意义(P<0.05)。结论对HBe Ag低效价慢性乙型肝炎患者行阿德福韦酯联合聚乙二醇干扰素α-2a治疗可以有效抑制HBe Ag阴性慢性乙型肝炎患者体内的HBV表达和复制。
Objective To investigate the specific efficacy of adefovir dipivoxil combined with pegylated interferon α-2a in patients with low-titer hepatitis B e antigen (HBe Ag) chronic hepatitis B. Methods Fifty patients with HBe Ag low titer and chronic hepatitis B were randomly divided into control group and experimental group with 25 cases in each group. Patients in the control group were treated with adefovir dipivoxil only. Patients in the test group were supplemented with peginterferon alfa-2a on the basis of adefovir dipivoxil treatment. The efficacy of the treatment was evaluated at weeks 24 and 48 after treatment, comparing the specific efficacy of the two regimens. Results The patients in the control group and the experimental group received different treatments, and the disease was relieved to some extent. After 48 weeks of treatment, virological response HBV-DNA conversion control group, 15 cases, 23 cases in the experimental group, the difference between the groups was statistically significant (P <0.05). HBsAg seroconversion control group 6 cases, the experimental group of 13 cases, the difference between the groups was statistically significant (P <0.05). Conclusion Adefovir dipivoxil combined with peginterferon alfa-2a can effectively inhibit HBV expression and replication in HBeAg-negative chronic hepatitis B patients.